FOSL1 and breast carcinoma: To validate the robustness of the FRA-1 transcriptional signature (generated from available gene expression data [18] (Table 1)) as a surrogate readout of FRA-1 activity, we used it to segregate breast cancer cells in which FRA-1 phosphorylation status was previously established (Fig. 2b).